Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Small Molecules

Manufacture Dosage Forms

Additive Benefits

| Hatim Cader

Will 3D inkjet printing enable the manufacture of personalized tablets?

Business & Regulation Small Molecules

And for 2020...

| Stephanie Sutton

Nominations are now open for The Medicine Maker 2020 Power List.

Manufacture Standards & Regulation

A Continuous Cycle of Success

| David Thompson

Helping to meet demands and reduce shortages... Is continuous manufacturing the way forward for pharma?

Discovery & Development Dosage Forms

Speed and Simplicity: A Formulator's Best Friend in Development

| Jayesh Parmar

From core to coating, there is a lot to consider when it comes to developing and optimizing a solid dosage formulation.

Manufacture Ingredients

A Lifetime of Achievement

| Maryam Mahdi

Sitting Down With... David Schoneker, Global Regulatory Director, Strategic Relationships at Colorcon.

Manufacture Small Molecules

Small, But Never Forgotten

| Stephanie Sutton

A new publication will give the small molecule manufacturing community the attention and praise it deserves. Meet The Small Molecule Manufacturer.

Manufacture Contract Manufacturing Services

Perks and Pitfalls of Antibody Drug Conjugates

| Stephanie Sutton

ADCs have suffered a few setbacks over the years, but interest in their therapeutic potential – particularly against cancer – remains high.

Manufacture Small Molecules

Battery-Powered Inspiration

| Maryam Mahdi

A battery-like system developed by scientists at Scripps Research could help enhance the manufacture of drugs.

Manufacture Biosimilars

It’s Complicated

| Bérangère Tissot

The potential market for complex generics is substantial, but navigating the FDA’s guidance for proving “sameness” is a real minefield...

Discovery & Development Small Molecules

Solutions in... Drug Development

| James Strachan

Douglas J. Swirsky, CEO of Rexahn Pharmaceuticals, explains his company’s approach to developing more effective cancer treatments.

Newsletter

Send me the latest from The Medicine Maker.

Sign up now

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register